Science Matters: A Druggable Target For PTEN-Deficient Prostate Cancer
Executive Summary
By taking a different slant on synthetic lethality – the therapeutic process behind AstraZeneca's Lynparza –scientists have identified a potential new drug target for use in prostate cancer, the chromatin helicase DNA-binding factor CHD1.